Phase I trial of ethyl eicosapentaenoic acid/rosuvastatin (AMR 102) in healthy volunteers
Latest Information Update: 27 Jun 2013
Price :
$35 *
At a glance
- Drugs Ethyl eicosapentaenoic acid/rosuvastatin (Primary) ; Ethyl eicosapentaenoic acid; Rosuvastatin
- Indications Cardiovascular disorders; Hyperlipidaemia
- Focus Pharmacokinetics
- 21 Jun 2013 Status changed from active, no longer recruiting to completed, according to Amarin Corporation media release.
- 21 Dec 2012 New trial record